CHRONIC MYELOMONOCYTIC LEUKEMIA

This early-stage study aims to find the safest dose of a new two-drug combination for adults with high-risk forms of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML). All 12 participants will first take an approved oral medi…

This study is testing a stem cell transplant from a partially matched family donor for patients with hard-to-treat blood cancers like leukemia and lymphoma. Before the transplant, patients receive chemotherapy and radiation to wipe out their own bone marrow and cancer cells. The …

This study is testing a new, lower-dose weekly schedule of two approved drugs (decitabine and venetoclax) for people with certain blood cancers like AML and MDS. The goal is to see if this gentler approach can control the cancer while causing fewer severe side effects and treatme…

This is a first-in-human study testing a new drug called STX-0712 in patients with advanced forms of blood cancer (CMML and AML) who have no remaining standard treatment options. The main goals are to find a safe dose and see if the drug shows any early signs of fighting the canc…

This study is testing whether a medication called canakinumab, given as a monthly injection, can help control certain low-risk blood and bone marrow disorders. It aims to see if the treatment improves blood counts, reduces the need for blood transfusions, and is safe for patients…

This study is testing if adding a drug called venetoclax to a standard chemotherapy and stem cell transplant regimen works better for adults with high-risk forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see if this combination helps contro…

This early-stage study is testing a new oral drug called EP0042, both alone and combined with other cancer treatments, in adults with advanced blood cancers like acute myeloid leukemia (AML). The main goal is to find a safe and tolerable dose. The study is for patients whose canc…

This study is testing a combination of two drugs, azacitidine and quizartinib, for adults with advanced forms of blood and bone marrow cancers (like myelodysplastic syndromes). The goal is to find the safest and most effective dose and see if the combination can help control thes…

This study is testing a targeted drug called enasidenib, sometimes combined with another drug (azacitidine), for people with a high-risk type of blood and bone marrow disorder called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to…

This study tests whether combining two medicines—enasidenib and azacitidine—can help control acute myeloid leukemia that has returned or hasn't responded to previous treatments. It's for patients whose cancer has a specific genetic change called an IDH2 mutation. Researchers want…

This early-stage study is testing a new treatment called CD4CAR for adults with Chronic Myelomonocytic Leukemia (CMML) that has come back or not responded to standard care. Doctors will collect a patient's own immune cells, engineer them in a lab to target cancer cells, and infus…

This study is testing a combination of three medications given after a stem cell transplant to prevent a dangerous complication called graft-versus-host disease (GVHD). It will enroll 124 adults with leukemia or similar blood cancers who are receiving a transplant from a donor. T…

This study is testing a modified, two-step stem cell transplant procedure designed to be safer. It aims to reduce deaths caused by the transplant treatment itself in patients with various blood cancers and disorders. The trial compares two gentler preparation methods using lower …

This study is testing a new experimental drug that delivers radiation directly to cancer cells in patients with high-risk blood cancers like acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The goal is to find the safest and most effective dose of this targete…

This study is testing a new treatment for aggressive blood cancers (like leukemia or MDS) that have come back or are not responding to standard therapies. The treatment involves a radioactive antibody designed to seek out and destroy cancer cells, followed by a stem cell transpla…

This study is testing a new oral pill called ASTX030 for people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The main goal is to see if the pill works as well as or better than the standard injected medication. It will also tes…

This study is testing whether adding the drug olutasidenib to standard chemotherapy can better control advanced blood cancers in patients who have a specific genetic mutation (IDH1). It aims to see if this combination is safe and effective at reducing the disease. The trial is fo…

This study is testing a new combination of two drugs, axatilimab and azacitidine, for people with advanced or hard-to-treat blood cancers. The first part of the study aims to find the safest and most effective dose. The second part will see how well the drug combination works to …

This study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…

This study is testing whether adding a new drug called IMM01 to standard treatment (azacitidine) works better for adults newly diagnosed with a rare blood cancer called chronic myelomonocytic leukemia (CMML). The main goals are to see if more patients achieve complete remission a…

This study is testing if adding high-dose vitamin C (given through an IV) to standard chemotherapy can help patients whose lymphoma has returned or hasn't responded to treatment. It also tests vitamin C alone for certain pre-leukemia conditions. The goal is to see if vitamin C ma…

This study is testing whether a pill called olutasidenib can help control certain early-stage blood disorders that have a specific genetic change (IDH1 mutation). It will involve about 15 adults with conditions like clonal cytopenia of undetermined significance (CCUS), lower-risk…

This early-stage trial is testing whether a drug called olutasidenib can safely prevent certain blood cancers from returning after a patient has received a donor bone marrow transplant. The study will enroll about 15 adults with acute myeloid leukemia, myelodysplastic syndrome, o…

This study is testing a new, faster treatment plan for adults aged 60 and older with aggressive blood cancers like acute myeloid leukemia (AML). The goal is to see if giving strong chemotherapy followed quickly by a lower-intensity stem cell transplant is safer and more effective…

This early-stage trial is testing a new cell therapy for children and adults whose leukemia has come back or persists after a donor stem cell transplant. Doctors take immune cells (T cells) from the original donor, genetically modify them to better recognize and attack the patien…